Stanford inventors have developed a nanoparticle containing the toll-like receptor agonist (TLR7-NP) that elicits a potent anti-tumor immune response in multiple cancer types without inducing undesired systemic inflammation and toxicity.
Spiral ganglion neurons (SGNs) are essential for hearing as they transmit electrical signals from the cochlea to the brain. Loss of SGNs causes permanent hearing loss because SGNs do not spontaneously regenerate in humans.
This invention is an innovative breakthrough in cancer radiotherapy, offering a cutting-edge solution to address the challenges of radio-resistant and immunosuppressive tumors.
Stanford researchers in the Lin Lab have identified kinase-modulated bioluminescent indicators (KiMBIs) which can assess real time kinase inhibition in target tissues in vivo.
Researchers at Stanford and the University of Helsinki discovered that a human secretoglobin protein found in sweat gland cells acts as a novel host defense mechanism against Lyme disease.
Researchers in the Burns group at Stanford designed a reaction methodology that allows for a green and inexpensive cycloaddition of amine or amide-containing unactivated olefins for the synthesis of biologically relevant cyclobutanes.
Stanford scientists in Dr. Paul Wender's lab have developed a novel method to synthesize tigilanol tiglate (EBC-46) and related compounds from readily available starting materials.
Researchers at Stanford have developed synthetic transcription elongation factors (Syn-TEFs) to treat proliferative diseases, including repeat expansion mutations in cancer.
Colorectal cancer affects 1.4 million new patients annually, with existing treatments often ineffective. A key factor in treatment resistance is high aldehyde dehydrogenase activity, which undermines several chemotherapies.
The blood-brain barrier is a huge challenge when it comes to the delivery of therapeutic proteins to treat genetic diseases, injury, and neurodegenerative diseases.
Antimicrobial peptoids are promising leads for novel antibiotics; however, their activity is often compromised under physiological conditions. Inventors at Stanford enhanced the efficacy of antimicrobial peptoids by using thiourea and thiourea derivatives.